Protalix BioTherapeutics

Protalix BioTherapeutics is a biopharmaceutical company that has revolutionized the development and production of recombinant therapeutic proteins through its ProCellEx® plant cell-based protein expression system. Protalix’s pipeline is led by ELELYSO™ (taliglucerase alfa for injection), which was approved by the U.S. Food and Drug Administration on May 1, 2012. ELELYSO is the first FDA-approved plant cell-based recombinant therapeutic protein.